Effect of intensive insulin therapy using a closed-loop glycemic control system in hepatic resection patients: a prospective randomized clinical trial

Takehiro Okabayashi MD\textsuperscript{1}, Isao Nishimori MD\textsuperscript{2}, Hiromichi Maeda MD\textsuperscript{1}, Koichi Yamashita MD\textsuperscript{3}, Tomoaki Yatabe MD\textsuperscript{3}, and Kazuhiro Hanazaki MD\textsuperscript{1}

\textsuperscript{1}Department of Surgery, \textsuperscript{2}Department of Gastroenterology and Hepatology, \textsuperscript{3}Department of Anesthesiology and Critical Care Medicine, Kochi Medical School

Address correspondence requests to:
Dr. Takehiro Okabayashi
\textit{E-mail: tokabaya@kochi-u.ac.jp}

Clinical trial reg. no. NCT00659698, clinicaltrials.gov


This is an uncopyedited electronic version of an article accepted for publication in \textit{Diabetes Care}. The American Diabetes Association, publisher of \textit{Diabetes Care}, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of \textit{Diabetes Care} in print and online at http://care.diabetesjournals.org.
**Objective:** Intensive insulin therapy (IIT) reduces morbidity and mortality in patients in surgical intensive care units. The aim of this study is to assess the effect of intensive insulin therapy using a closed-loop system in hepatectomized patients.

**Methods:** Patients were randomly assigned to receive IIT using a closed-loop system: an artificial pancreas (AP group) or conventional insulin therapy using the sliding scale method (SS group).

**Results:** The incidence of surgical site infection (SSI) in AP group was significantly lower than that in SS group. The length of hospitalization required for patients in AP group was significantly shorter than that in SS group.

**Conclusions:** Total hospital costs for patients in AP group were significantly lower than for those in SS group. IIT using a closed-loop system maintained near-normoglycemia and contributed to a reduction in the incidence of SSI and total hospital costs due to shortened hospitalization.
Large randomized trials in which the use of tight blood glucose control with intensive insulin therapy (IIT) was compared to standard blood glucose control in surgical intensive care unit (ICU) patients have demonstrated that strict control of postoperative blood glucose levels not only significantly reduced patient mortality, but also reduced morbidity. These results helped initiate several short-lived multi-center randomized control studies designed to evaluate the benefit of tight glycemic control (TGC) with IIT. Unfortunately, however, these clinical trials were stopped early mainly because of the high incidence of hypoglycemia (10-17%) induced by IIT.

Considering the frequency of the use of IIT in patients undergoing surgical treatment in the ICU, we conducted a prospective randomized controlled trial to evaluate the postoperative condition of the patients and the effect of a closed-loop artificial pancreas on TGC during IIT in hepatectomized patients.

**RESEARCH DESIGN AND METHODS**

Of the 91 people approached to take part in this prospective randomized study, 88 agreed to participate. Patients were informed of the purpose and details of the study, and written consent was obtained from them prior to enrolment. The study was approved by the local ethics committee at the Kochi Medical School and carried out in accordance with the Helsinki Declaration. All studies were performed between April 2007 and June 2008. We prospectively divided patients into two groups: one for whom glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale (SS group, n = 44), and a second group that received programmed infusions of insulin determined by the control algorithm of the closed-loop system (AP group, n = 44).

The primary endpoint of this study was to determine whether the incidence of SSI is reduced by perioerative TGC. SSI was monitored just after operation until discharge by the infection control team at our institute. The secondary endpoint was to evaluate the costs during the hospital stay in each patient group.

Continuous variables are presented as the mean ± SD. Dichotomous variables are presented as both number and percentage values. P < 0.05 was considered significant. Data were analyzed using the Student’s t test (two-tailed), with dichotomous variables analyzed by the χ² test (two-tailed) or Fisher’s exact test (two-tailed).

**RESULTS**

There was also no difference in the laboratory data, including nutritional parameters, liver function, fasting insulin concentration, and fasting blood glucose level between the two groups. Diabetes mellitus (DM) status was checked by diabetologist and diabetic subjects were all Type 2. The presence of a previous medical history for DM was equally distributed between the two groups (31.8% in SS group and 38.6% in AP group, respectively). There was no significant predisposition to these operative procedures between the two groups. The operation time and estimated volume of blood loss did not differ significantly between the two groups. Final liver tumor diagnoses were hepatocellular carcinoma in 29 patients and adenocarcinoma in 15 patients in both the SS and AP groups. There were no operative mortalities (0%) 30 days after hepatic resection in either group, and all patients were discharged.

Neither group experienced hypoglycemia (< 40 mg/dL). Perioperative blood glucose levels in the AP group were
near 100 mg/dL, but those in the SS group were greater than 150 mg/dL. Mean blood glucose levels were adequately controlled by a closed-loop glycemic control system (Figure). The percentage in blood glucose target at very tight control (80 – 110 mg/dL) and moderately tight control (< 140 mg/dL) by a closed-loop system during surgical ICU were at least more than 60% and 85%, respectively (Figure). In contrast, the postoperative glucose control according to sliding scale method were very poor. In all of the SS-group patients, the total insulin used according to the routine sliding scale was below 24 units. In the patients in the AP group, a total amount of 175 ± 93 units of insulin was consumed for IIT managed by the STG-22 for 18 hours after the hepatic resection. The incidence of SSI in the AP group was significantly lower than that in the SS group ($P = 0.030$). It is of note that patients in the AP group required a significantly shorter hospitalization than patients in the SS group ($P = 0.049$). The total hospital actual costs, including the costs of using the closed-loop system, for the original surgical admission of patients in the AP group ($16,407$) were significantly lower than those for patients in the SS group ($21,879$; $P = 0.047$). None of the patients in the present study required operation-related re-admission.

CONCLUSION

The risk of severe hypoglycemia (glucose < 40 mg/dL) with IIT has been shown to increase from 5.1 to 18.7% in ICU studies. In the present study, there were no occurrences of hypoglycemia. Clearly, we support a recent report that suggests the development of accurate, continuous blood glucose monitoring devices, and preferably closed-loop systems for computer-assisted blood glucose control in the ICU, will help avoid hypoglycemia.

A limited number of studies describing SSI after hepatic resection have reported a wide-ranging incident rate of 10.8-26.0%. The total caloric requirement was calculated according to the Harris-Benedict equation. The results of our study proposed that controlling postoperative glucose levels using insulin therapy and maintaining an adequate calorie level contributed to a reduction in the incidence of SSI (2.3% vs 18.2%). In the current study, TGC was performed for 18 hours in patients with liver resection at surgical ICU and excellent glucose control was successfully observed without hypoglycemia by using closed-loop system. We strongly believe that perioperative TGC for an abbreviated period (at least for 18 hours) from the postoperative early stage had a prevention of postoperative infectious morbidities.

When the overall costs during hospitalization were calculated, patients with SSI had a crude median cost of $28,681 compared to $16,352 for uninfected patients ($P < 0.001$). This is the first report that demonstrates that perioperative TGC might reduce the incidence of postoperative SSI and decrease the total costs associated with hospitalization for patients undergoing hepatic surgery for liver neoplasm.

ACKNOWLEDGMENTS

This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Pancreas Research Foundation of Japan, and The Kochi University President’s Discretionary Grant. Financial support: Supported by the Ministry of Education, Culture, Sports, Science, and Technology, Pancreas Research Foundation of Japan, and The Kochi University President’s Discretionary Grant.
REFERENCES
12. Van den Berghe G. Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l Diabetologia 2008; 51: 911–915.
Figure Postoperative blood glucose levels monitored using the closed-loop system in the sliding scale (solid line) and artificial pancreas (broken line) groups (mean blood glucose, $P < 0.01$)

% in target on glycemic levels by sliding scale method

<table>
<thead>
<tr>
<th>Blood glucose level</th>
<th>% in target</th>
</tr>
</thead>
<tbody>
<tr>
<td>80-110 mg/dL</td>
<td>22.7</td>
</tr>
<tr>
<td>&lt; 140 mg/dL</td>
<td>45.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood glucose level</th>
<th>% in target</th>
</tr>
</thead>
<tbody>
<tr>
<td>80-110 mg/dL</td>
<td>75.0</td>
</tr>
<tr>
<td>&lt; 140 mg/dL</td>
<td>90.9</td>
</tr>
</tbody>
</table>

% in target on glycemic levels by closed-loop system

<table>
<thead>
<tr>
<th>Blood glucose level</th>
<th>% in target</th>
</tr>
</thead>
<tbody>
<tr>
<td>80-110 mg/dL</td>
<td>59.1</td>
</tr>
<tr>
<td>&lt; 140 mg/dL</td>
<td>86.4</td>
</tr>
</tbody>
</table>